THERAPEUTIC AREA
saveOphthalmology
Diseases of the eye and visual system.
also known as: eye, vision, ocular
🐶 often sniffed alongside
top 8- tagApproval176 co-mentions · 88 sources
- tagRecall128 co-mentions · 36 sources
- drugapraclonidine hydrochloride88 co-mentions · 44 sources
- tagAdCom60 co-mentions · 53 sources
- drugFlarex56 co-mentions · 28 sources
- company$CAHCARDINAL HEALTH INC38 co-mentions · 5 sources
- tag510(k) Clearance31 co-mentions · 26 sources
- tagPMA Approval29 co-mentions · 27 sources
drugs
368
catalysts
16
news
719
companies
258
Top drugs
view all →Marketed
Restasis
Keratoconjunctivitis Sicca (Dry Eye)
$ABBV · 123 catalysts
Marketedadalimumab
Intermediate Uveitis
$ABBV · 61 catalysts
MarketedDOXYCYCLINE HYCLATE
$AMRX · 49 catalysts
Marketedmethylprednisolone sodium succinate
Drug Hypersensitivity Reactions
48 catalysts
MarketedMETHYLPREDNISOLONE ACETATE
Giant Cell Arteritis (Temporal Arteritis/Cranial Arteriti…
41 catalysts
Marketedprednisolone acetate
Anterior Segment Inflammation
$ABBV · 37 catalysts
MarketedMEDROL
$PFE · 34 catalysts
MarketedMINOCYCLINE HYDROCHLORIDE
Actinomycosis
34 catalysts
🐶 Top companies
view all →Recent catalysts
view all →Apr 30, 2026
phase 2 completion
Shenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)
umbilical cord mesenchymal stem cells derived apoptotic vesicles
→
Apr 30, 2026
phase 1 2 completion
Eyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)
MK-8748
→
Apr 30, 2026
phase 1 completion
Ilife Consulting Sarl — PST-611 (Phase I Trial Completion)
PST-611
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 29, 2026
phase 3 initiation
All India Institute of Medical Sciences Bathinda — mitomycin (Phase III Trial Initiation)
Jelmyto
→
Apr 29, 2026
phase 2 completion
Massachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)
N-acetylcysteine
→
Recent news
view all →- Bayer unpacks plans for $2.2B manufacturing site in Ohioendpoints · 2d ago
- Geographic atrophy biotech Aviceda to shut down after Phase 2 failendpoints · 2d ago
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingbiopharma dive · 2d ago
- As CDC redesigns annual health survey, it removes questions about disabilitiesstat · 3d ago
- M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buybiospace · 3d ago
- VertigoDx on firm ground with FDA greenlight for vertigo diagnostic systemfiercebiotech · 4d ago
- Ascletis challenges psoriasis field with pill; Invivyd plans Covid filingendpoints · 5d ago
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futurefiercebiotech · 6d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that